On : 23 june 2025
• The global rotator cuff biological mesh market size was valued at USD 138 million in 2024. The market is projected to grow from USD 148 million in 2025 to USD 230 million by 2032, exhibiting a CAGR of 7.7% during the forecast period.
Email: help@intelmarketresearch.com +91 9169164321
• Rotator cuff biological mesh is a specialized medical implant used in the surgical repair of torn rotator cuff tendons. These meshes are derived from biological materials such as porcine or fish-derived tissues, designed to reinforce damaged tendons while promoting natural tissue regeneration. Unlike synthetic alternatives, biological meshes minimize immune reactions and integrate seamlessly with the patient’s anatomy, improving long-term functional recovery.
• The market is witnessing steady growth, driven by the rising incidence of rotator cuff injuries, particularly among aging populations and athletes. While traditional sutures remain widely used, biological meshes offer advantages like reduced scar tissue formation and better biocompatibility. However, challenges such as high costs and limited long-term efficacy data could hinder adoption. Key players like Stryker, Arthrex, and CONMED are investing in advanced biologics to address these gaps, further propelling market expansion.Among the most prevalent tendon injuries, rotator cuff tears affect more than 17 million people in the United States each year. The incidence of injury increases with age: more than 40% of the population over 65 years old experience a rotator cuff tear.
Email:
•Human Dermal Allografts
•Xenografts
•Synthetic-Biologic Hybrid Mesh
•Others
Partial-Thickness Rotator Cuff Tears
Full-Thickness Rotator Cuff Tears
Massive/Irreparable Rotator Cuff Tears
Arthrex, Inc. (U.S.)
CONMED Corporation (U.S.)
Stryker Corporation (U.S.)
Zimmer Biomet Holdings, Inc. (U.S.)
Smith & Nephew plc (U.K.)
